Search research articles
Contact Us
Filters
Showing results (81-90 of 177) with videos related to
Page
of 18
Sort By:
Cells
|
May 24, 2024
Pre-Clinical Assessment of SAR442257, a CD38/CD3xCD28 Trispecific T Cell Engager in Treatment of Relapsed/Refractory Multiple Myeloma
Anna Luise Grab, Peter S Kim, Lukas John, et al.
Oncoimmunology
|
October 6, 2018
The prognostic and predictive value of IKZF1 and IKZF3 expression in T-cells in patients with multiple myeloma
Mohamed H S Awwad, Katharina Kriegsmann, Julian Plaumann, et al.
The Lancet. Haematology
|
March 15, 2020
MOR202, a novel anti-CD38 monoclonal antibody, in patients with relapsed or refractory multiple myeloma: a first-in-human, multicentre, phase 1-2a trial
Marc S Raab, Monika Engelhardt, Antje Blank, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 12, 2022
Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Final Overall Survival Analysis From the Randomized Phase II ELOQUENT-3 Trial
Meletios A Dimopoulos, Dominik Dytfeld, Sebastian Grosicki, et al.
Blood Advances
|
August 17, 2022
Characterizing the role of the immune microenvironment in multiple myeloma progression at a single-cell level
Carolina Schinke, Alexandra M Poos, Michael Bauer, et al.
The Lancet. Haematology
|
December 22, 2015
Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b-2 dose-escalation study
Paul G Richardson, Sundar Jagannath, Philippe Moreau, et al.
British Journal of Haematology
|
March 19, 2016
Single versus tandem high-dose melphalan followed by autologous blood stem cell transplantation in multiple myeloma: long-term results from the phase III GMMG-HD2 trial
Elias K Mai, Axel Benner, Uta Bertsch, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
June 3, 2026
Interpreting [<sup>18</sup>F]FDG-avid fractures after induction therapy in multiple myeloma: insights from the PET/CT sub-study of the Phase 3 GMMG-HD7 trial
Christos Sachpekidis, Marina Hajiyianni, Markus Wennmann, et al.
Haematologica
|
May 13, 2017
Longitudinal fluorescence <i>in situ</i> hybridization reveals cytogenetic evolution in myeloma relapsing after autologous transplantation
Maximilian Merz, Anna Jauch, Thomas Hielscher, et al.
The New England Journal of Medicine
|
November 8, 2018
Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma
Meletios A Dimopoulos, Dominik Dytfeld, Sebastian Grosicki, et al.
Page
of 18
Search research articles
Search
Showing results (81-90 of 177) with videos related to
Sort By:
Page
of 18
Cells
|
May 24, 2024
Pre-Clinical Assessment of SAR442257, a CD38/CD3xCD28 Trispecific T Cell Engager in Treatment of Relapsed/Refractory Multiple Myeloma
Anna Luise Grab, Peter S Kim, Lukas John, et al.
Oncoimmunology
|
October 6, 2018
The prognostic and predictive value of IKZF1 and IKZF3 expression in T-cells in patients with multiple myeloma
Mohamed H S Awwad, Katharina Kriegsmann, Julian Plaumann, et al.
The Lancet. Haematology
|
March 15, 2020
MOR202, a novel anti-CD38 monoclonal antibody, in patients with relapsed or refractory multiple myeloma: a first-in-human, multicentre, phase 1-2a trial
Marc S Raab, Monika Engelhardt, Antje Blank, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 12, 2022
Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Final Overall Survival Analysis From the Randomized Phase II ELOQUENT-3 Trial
Meletios A Dimopoulos, Dominik Dytfeld, Sebastian Grosicki, et al.
Blood Advances
|
August 17, 2022
Characterizing the role of the immune microenvironment in multiple myeloma progression at a single-cell level
Carolina Schinke, Alexandra M Poos, Michael Bauer, et al.
The Lancet. Haematology
|
December 22, 2015
Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b-2 dose-escalation study
Paul G Richardson, Sundar Jagannath, Philippe Moreau, et al.
British Journal of Haematology
|
March 19, 2016
Single versus tandem high-dose melphalan followed by autologous blood stem cell transplantation in multiple myeloma: long-term results from the phase III GMMG-HD2 trial
Elias K Mai, Axel Benner, Uta Bertsch, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
June 3, 2026
Interpreting [<sup>18</sup>F]FDG-avid fractures after induction therapy in multiple myeloma: insights from the PET/CT sub-study of the Phase 3 GMMG-HD7 trial
Christos Sachpekidis, Marina Hajiyianni, Markus Wennmann, et al.
Haematologica
|
May 13, 2017
Longitudinal fluorescence <i>in situ</i> hybridization reveals cytogenetic evolution in myeloma relapsing after autologous transplantation
Maximilian Merz, Anna Jauch, Thomas Hielscher, et al.
The New England Journal of Medicine
|
November 8, 2018
Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma
Meletios A Dimopoulos, Dominik Dytfeld, Sebastian Grosicki, et al.
Page
of 18